Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViatrisXSWX:VTRS -0.50%63 EV-to-OCF is 13.51 as of Aug. 16, 2026, which is 8% above its 10-year median of 12.56. GuruFocus rates XSWX:VTRS with a GF Score™ of 63/100 and a GF Value™ of CHF9.27. The stock has 8 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Viatris ranks worse than 55.86% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Viatris's Enterprise Value is CHF25,043 Mil.
Viatris's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was CHF1,854 Mil. Therefore, Viatris's EV-to-OCF for today is 13.51.
The historical rank and industry rank for Viatris's EV-to-OCF or its related term are showing as below:
XSWX:VTRS'
s EV-to-OCF Range Over the Past 10 Years
Min: 8.71 Med: 12.56 Max: 33.39
Current: 13.2
During the past 13 years, the highest EV-to-OCF of Viatris was 33.39. The lowest was 8.71. And the median was 12.56.
XSWX:VTRS's EV-to-OCF is ranked worse than 55.86% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.025
vs XSWX:VTRS: 13.20
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-08-16), Viatris's stock price is CHF13.188.
Viatris's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was CHF-0.289. Therefore, Viatris's PE Ratio (TTM) for today is At Loss.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Viatris's share price for today is CHF13.188.
Viatris's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-0.289.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Viatris EV-to-OCF Related Terms
Viatris EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Viatris's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:VTRS vs UTHR, NBIX, ELAN: EV-to-OCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Viatris's EV-to-OCF falls into.
Viatris's current Enterprise Value is CHF25,043 Mil.
Viatris's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1,854 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (XSWX:VTRS) has a EV-to-OCF of 13.51 as of Aug. 16, 2026. This is near median its historical median of 12.56. Over the past decade, Viatris' EV-to-OCF has ranged from 8.71 to 33.39. According to the industry distribution chart, Viatris ranks #562 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 55.9%.
Is Viatris' EV-to-OCF too high?
Viatris' current EV-to-OCF of 13.51 is near median its 10-year median of 12.56. Over the past 10 years, this metric has ranged from a low of 8.71 to a high of 33.39. The Drug Manufacturers industry median EV-to-OCF is 11.03. Viatris' value of 13.51 is 22.5% above this industry median. Based on the distribution chart, Viatris ranks #562 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Viatris has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Viatris' EV-to-OCF compare to UTHR and NBIX?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #562 out of 1006 companies for EV-to-OCF. This places Viatris in the lower half of its industry. The industry median EV-to-OCF is 11.03. Viatris' value of 13.51 is 22.5% above this benchmark. Historically, Viatris' own EV-to-OCF has ranged from 8.71 to 33.39 over the past decade. While the company's 10-year median is 12.56 vs. the industry median of 11.03, Viatris has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.03, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current EV-to-OCF of 13.51 is 22.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current EV-to-OCF is 13.51, which is near median its own 10-year median of 12.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Viatris (XSWX:VTRS) has a current EV-to-OCF of 13.51. The stock's GF Value™ is CHF9.27, compared to a current price of CHF13.19 — trading 42.3% above its estimated fair value. The current EV-to-OCF is 13.51, which is near median its 10-year median of 12.56 and 22.5% above the Drug Manufacturers industry median of 11.03. Viatris' overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Viatris (XSWX:VTRS), the current EV-to-OCF is 13.51 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (XSWX:VTRS) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of CHF13.19 is trading 42.3% above its estimated GF Value™ of CHF9.27.
Key valuation signals for XSWX:VTRS:
EV-to-OCF: 13.51 (near median its 10-year median of 12.56)
GF Value™: CHF9.27 vs. price of CHF13.19 (42.3% above fair value)
Industry Position: 22.5% above the Drug Manufacturers median (#562 of 1006)
No single metric tells the full story. See the XSWX:VTRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
63GF Score
Get the complete analysis for XSWX:VTRS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:VTRS has been successfully added to your 
